Unknown

Dataset Information

0

The neoepitope landscape of breast cancer: implications for immunotherapy.


ABSTRACT:

Background

Cancer immunotherapy with immune checkpoint blockade (CKB) is now standard of care for multiple cancers. The clinical response to CKB is associated with T cell immunity targeting cancer-induced mutations that generate novel HLA-binding epitopes (neoepitopes).

Methods

Here, we developed a rapid bioinformatics pipeline and filtering strategy, EpitopeHunter, to identify and prioritize clinically relevant neoepitopes from the landscape of somatic mutations. We used the pipeline to determine the frequency of neoepitopes from the TCGA dataset of invasive breast cancers. We predicted HLA class I-binding neoepitopes for 870 breast cancer samples and filtered the neoepitopes based on tumor transcript abundance.

Results

We found that the total mutational burden (TMB) was highest for triple-negative breast cancer, TNBC, (median = 63 mutations, range: 2-765); followed by HER-2(+) (median = 39 mutations, range: 1-1206); and lowest for ER/PR(+)HER-2(-) (median = 32 mutations, range: 1-2860). 40% of the nonsynonymous mutations led to the generation of predicted neoepitopes. The neoepitope load (NEL) is highly correlated with the mutational burden (R2 = 0.86).

Conclusions

Only half (51%) of the predicted neoepitopes are expressed at the RNA level (FPKM≥2), indicating the importance of assessing whether neoepitopes are transcribed. However, of all patients, 93% have at least one expressed predicted neoepitope, indicating that most breast cancer patients have the potential for neo-epitope targeted immunotherapy.

SUBMITTER: Narang P 

PROVIDER: S-EPMC6399957 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

The neoepitope landscape of breast cancer: implications for immunotherapy.

Narang Pooja P   Chen Meixuan M   Sharma Amit A AA   Anderson Karen S KS   Wilson Melissa A MA  

BMC cancer 20190304 1


<h4>Background</h4>Cancer immunotherapy with immune checkpoint blockade (CKB) is now standard of care for multiple cancers. The clinical response to CKB is associated with T cell immunity targeting cancer-induced mutations that generate novel HLA-binding epitopes (neoepitopes).<h4>Methods</h4>Here, we developed a rapid bioinformatics pipeline and filtering strategy, EpitopeHunter, to identify and prioritize clinically relevant neoepitopes from the landscape of somatic mutations. We used the pipe  ...[more]

Similar Datasets

| S-EPMC8452050 | biostudies-literature
| S-EPMC5577668 | biostudies-literature
| S-EPMC9306193 | biostudies-literature
| S-EPMC8657247 | biostudies-literature
| S-EPMC9893403 | biostudies-literature
| S-EPMC9730156 | biostudies-literature
| S-EPMC9437219 | biostudies-literature
| S-EPMC8425706 | biostudies-literature
| S-EPMC8199088 | biostudies-literature
| S-EPMC10693334 | biostudies-literature